Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Reporting date: August 14, 2023. The filing reports entry into a definitive merger agreement with Zynerba Pharmaceuticals, Inc.; it does not provide quarterly or annual financial statements.
Business Context and Transaction Terms
- Harmony and its wholly owned subsidiary, Xylophone Acquisition Corp., agreed to acquire all outstanding Zynerba common stock through a tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law.
- The cash consideration is $1.1059 per Zynerba share, plus one non-transferable contingent value right (CVR) per share.
- Each CVR may provide up to approximately $2.5444 per share, subject to achievement of specified development, regulatory and sales milestones. The minimum CVR payment is zero.
- The tender offer was expected to expire at 5:00 p.m. New York time on the date 21 business days after commencement, subject to extensions. The offer had not commenced as of the filing date.
- Completion is subject to customary conditions, including valid tenders representing more than 50% of Zynerba’s outstanding shares, regulatory and legal conditions, accuracy of representations and warranties, and compliance with covenants.
- The merger is intended to follow completion of the tender offer without a separate Zynerba stockholder vote.
Contingent Value Rights and Milestones
- $15 million upon completion of the final patient’s final visit in the RECONNECT pivotal study for Zygel by June 30, 2026.
- $30 million, $20 million or $10 million if the pivotal study meets its primary endpoints, depending on the timing of achievement.
- $35 million upon U.S. NDA approval for the first indication and $15 million upon NDA approval for a second indication.
- $15 million upon worldwide cumulative net sales of at least $250 million, and $30 million upon worldwide cumulative net sales of at least $500 million, subject to the stated conditions.
- CVR rights terminate on December 31, 2040. The filing states that there can be no assurance that any milestone will be achieved or any contingent payment made.
Financial Metrics, Liquidity and Debt
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, liquidity measures or transaction funding details. It also does not quantify expected synergies, integration costs or the aggregate purchase price, because the number of shares subject to the offer is not stated.
Material Changes Versus the Prior Comparable Period
No comparable-period financial information is included. The material development disclosed is Harmony’s execution of the Zynerba merger agreement and related support agreements.
Guidance, Outlook, Risks and Unusual Items
- Zynerba directors and executive officers agreed to tender their shares, support the merger and generally refrain from transferring their shares. They beneficially owned approximately 6.9% of Zynerba’s outstanding shares as of August 14, 2023.
- Zynerba may consider an unsolicited superior proposal under specified fiduciary-out provisions. A $4.5 million termination fee may be payable to Harmony in certain circumstances involving a competing acquisition proposal.
- Either party may terminate under specified circumstances, including failure to complete the transaction by November 12, 2023, legal prohibition, failure of offer conditions or uncured breach.
- Key risks include insufficient shareholder tenders, delayed or failed closing, regulatory or legal impediments, integration difficulties, unexpected costs, loss of employees or third-party relationships, failure to realize anticipated benefits, and the possibility that no CVR payments become payable.
- The transaction remains subject to the tender offer and merger conditions. Harmony and Merger Sub stated that they would file tender offer materials on Schedule TO, while Zynerba would file a Schedule 14D-9.
Important Facts for Investors to Verify
- Whether the tender offer commenced and whether the required majority of Zynerba shares were validly tendered.
- Whether all regulatory, legal and other closing conditions were satisfied or waived, and whether the merger closed by the applicable deadline.
- The final number of shares, options and restricted awards receiving consideration and the resulting total cash obligation.
- The definitive CVR terms, including milestone definitions, achievement deadlines, payment calculations and administrative provisions.
- Subsequent disclosures regarding Zygel’s clinical development, regulatory approvals, commercial sales and any CVR payments.
- Harmony’s later financial statements for the accounting treatment, transaction costs, funding sources, liquidity impact and post-closing operating results.